Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Pfizer Inc. pages available for free this week:
- Balance Sheet: Assets
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Pfizer Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
The liquidity position, as indicated by the current, quick, and cash ratios, exhibits considerable fluctuation over the observed period. Generally, ratios demonstrate an increasing trend through much of 2023 before declining again into 2024 and stabilizing in late 2024 and 2025.
- Current Ratio
- The current ratio began at 1.39 and generally increased, peaking at 2.38 in October 2023. A significant decrease followed, reaching a low of 0.91 by December 2023. The ratio then recovered somewhat, fluctuating between 1.00 and 1.28 over the subsequent quarters, concluding at 1.16. This pattern suggests periods of improved short-term asset coverage followed by periods of potential liquidity strain.
- Quick Ratio
- The quick ratio mirrors the trend of the current ratio, starting at 0.95 and rising to a high of 1.78 in October 2023. A substantial decline occurred in the following quarter, dropping to 0.50. Subsequent quarters show a recovery, but remain lower than the peak, ranging from 0.56 to 0.80. The final reported value is 0.69. This indicates that the company’s ability to meet short-term obligations with its most liquid assets also experiences volatility.
- Cash Ratio
- The cash ratio demonstrates a similar pattern of increase followed by decrease. It began at 0.61, peaked at 1.42 in October 2023, and then fell sharply to 0.27 by December 2023. The ratio experienced modest recovery, fluctuating between 0.23 and 0.48 before stabilizing around 0.37-0.41 in the final reported periods. This suggests a significant reliance on cash to cover immediate liabilities, with periods of stronger and weaker cash positions.
The pronounced declines in all three ratios during the December 2023 timeframe warrant further investigation. The subsequent partial recoveries suggest corrective actions were taken, but the ratios have not consistently returned to their earlier levels. The overall trend indicates a dynamic liquidity situation requiring ongoing monitoring.
Current Ratio
| Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Current assets | |||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||
| Current ratio1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Current Ratio, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The current ratio exhibited considerable fluctuation throughout the observed period. Initially, the ratio demonstrated a modest increase from 1.39 in April 2022 to 1.59 in October 2022, suggesting improving short-term liquidity. A subsequent decline to 1.22 was noted by December 2022, followed by a slight recovery to 1.37 in April 2023.
A significant surge in the current ratio occurred between April 2023 and July 2023, reaching a peak of 2.12. This improvement continued into October 2023, with the ratio reaching 2.38. However, a substantial decrease followed, dropping to 0.91 by December 2023. This represents a considerable weakening in the company’s ability to cover its short-term obligations with its short-term assets.
- Trend Analysis (April 2022 – December 2023)
- The period began with relative stability, followed by a period of growth, and then a dramatic decline in the current ratio. The decline in late 2023 is particularly noteworthy, falling below the generally accepted benchmark of 1.0, indicating potential liquidity concerns.
The ratio experienced a partial recovery in the subsequent quarters, rising to 1.17 by December 2024. This upward trend continued into March 2025, reaching 1.26, before decreasing slightly to 1.16 in June 2025. A minor increase to 1.28 was observed in September 2025, but the ratio concluded the period at 1.16 in December 2025.
- Recent Performance (January 2024 – December 2025)
- The most recent period demonstrates a more stable, albeit modest, current ratio. While the ratio improved from the low of 0.91 in December 2023, it has not consistently exceeded 1.3, suggesting ongoing, though lessened, liquidity pressures. The final value of 1.16 indicates a continued need for monitoring of short-term asset and liability management.
Overall, the current ratio demonstrates a pattern of volatility. While periods of strong liquidity are evident, the significant decline in late 2023 and the subsequent stabilization around 1.16 suggest potential underlying factors impacting the company’s short-term financial health that warrant further investigation.
Quick Ratio
| Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||
| Short-term investments | |||||||||||||||||||||
| Trade accounts receivable, net of allowance for doubtful accounts | |||||||||||||||||||||
| Total quick assets | |||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||
| Quick ratio1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Quick Ratio, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The quick ratio exhibited considerable fluctuation throughout the observed period, spanning from April 2022 to December 2025. Initially, the ratio demonstrated an improving trend, peaking in October 2023, before experiencing a significant decline and subsequent stabilization. Overall, the company’s ability to meet short-term obligations using its most liquid assets varied considerably.
- Initial Period (Apr 2022 – Oct 2023)
- From April 2022 to October 2023, the quick ratio generally increased. Starting at 0.95, it rose to a high of 1.78 in October 2023. This indicates a strengthening ability to cover current liabilities with readily available assets during this timeframe. The most substantial increase occurred between April 2023 and October 2023, suggesting a strategic improvement in liquidity management or a shift in asset composition.
- Subsequent Decline (Oct 2023 – Mar 2024)
- Following the peak in October 2023, a marked decline in the quick ratio was observed. The ratio decreased from 1.78 to 0.42 by April 2024. This substantial drop suggests a potential strain on short-term liquidity, possibly due to increased current liabilities or a decrease in quick assets. The decline was particularly pronounced between October 2023 and April 2024.
- Stabilization and Recent Trend (Mar 2024 – Dec 2025)
- From March 2024 through December 2025, the quick ratio demonstrated a degree of stabilization, fluctuating between 0.42 and 0.80. While not consistently strong, the ratio avoided further significant declines. The most recent value, 0.69 in December 2025, indicates a slight improvement from the low point in April 2024, but remains below the levels observed in the earlier part of the period. The ratio has remained relatively consistent in the last four quarters.
- Underlying Asset and Liability Movements
- The fluctuations in the quick ratio correlate with movements in both total quick assets and current liabilities. The peak in the ratio in October 2023 coincided with high levels of quick assets and relatively lower current liabilities. Conversely, the decline in early 2024 was associated with a decrease in quick assets and an increase in current liabilities. The recent stabilization appears to be a result of relatively stable levels of both assets and liabilities.
In conclusion, the quick ratio indicates a dynamic liquidity position. While periods of strong liquidity were observed, the company experienced a notable decline in its ability to cover short-term obligations, followed by a period of stabilization. Continued monitoring of this ratio, alongside its underlying components, is recommended.
Cash Ratio
| Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||
| Short-term investments | |||||||||||||||||||||
| Total cash assets | |||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||
| Cash ratio1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Cash Ratio, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The cash ratio exhibited considerable fluctuation throughout the observed period, spanning from April 2022 to December 2025. Initially, the ratio demonstrated an increasing trend, peaking in October 2023, before experiencing a substantial decline and subsequent moderate recovery.
- Initial Trend (Apr 2022 – Oct 2023)
- From April 2022 (0.61) to October 2023 (1.42), the cash ratio generally increased, indicating a strengthening ability to meet current liabilities with immediately available cash. The most significant increase occurred between July 2023 (1.29) and October 2023 (1.42). This period suggests improved liquidity management or a strategic accumulation of cash assets.
- Significant Decline (Oct 2023 – Dec 2023)
- A dramatic decrease in the cash ratio was observed from October 2023 (1.42) to December 2023 (0.27). This sharp decline suggests a significant outflow of cash, potentially due to debt repayment, substantial investments, or other large expenditures, coupled with a rise in current liabilities. This represents the most substantial shift in the observed period.
- Subsequent Fluctuations and Recovery (Dec 2023 – Dec 2025)
- Following the decline, the cash ratio fluctuated between 0.27 and 0.48 through March 2025. A slight upward trend is discernible in the latter half of the period, with the ratio reaching 0.37 by December 2025. While this indicates some recovery in the company’s immediate liquidity position, it remains considerably lower than the peak observed in October 2023. The ratio remained below 0.50 for the majority of this period.
- Total Cash Assets and Current Liabilities
- The fluctuations in the cash ratio correlate with movements in both total cash assets and current liabilities. While cash assets increased significantly in July 2023, the subsequent decline in the cash ratio suggests that the increase in current liabilities, particularly in December 2023, outweighed the benefit of the increased cash holdings. The relatively stable current liabilities in the final period (September 2025 – December 2025) contributed to the slight recovery in the cash ratio.
Overall, the cash ratio demonstrates a volatile pattern. The company experienced periods of strong liquidity, followed by a substantial decrease and a partial, albeit limited, recovery. Continued monitoring of both cash asset levels and current liabilities is recommended to understand the underlying drivers of these fluctuations and to assess the company’s ongoing liquidity position.